Modified factor VII
US6183743A · kind A · utility
26Cited by
17References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 20, 1999 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Aug 20, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/4846
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.